Charles Schwab Investment Management Inc. Makes New Investment in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

Charles Schwab Investment Management Inc. purchased a new stake in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 33,079 shares of the biotechnology company’s stock, valued at approximately $82,000.

A number of other hedge funds and other institutional investors have also modified their holdings of ACRS. Geode Capital Management LLC increased its stake in Aclaris Therapeutics by 9.3% during the 3rd quarter. Geode Capital Management LLC now owns 846,446 shares of the biotechnology company’s stock valued at $974,000 after buying an additional 72,309 shares during the period. Assenagon Asset Management S.A. boosted its holdings in shares of Aclaris Therapeutics by 113.9% in the fourth quarter. Assenagon Asset Management S.A. now owns 397,362 shares of the biotechnology company’s stock valued at $985,000 after acquiring an additional 211,585 shares in the last quarter. Peapod Lane Capital LLC acquired a new position in shares of Aclaris Therapeutics during the fourth quarter valued at approximately $1,003,000. Finally, Jacobs Levy Equity Management Inc. acquired a new position in shares of Aclaris Therapeutics during the third quarter valued at approximately $1,053,000. 98.34% of the stock is currently owned by institutional investors.

Aclaris Therapeutics Stock Down 3.3 %

Shares of Aclaris Therapeutics stock opened at $1.48 on Wednesday. Aclaris Therapeutics, Inc. has a 12-month low of $0.95 and a 12-month high of $5.17. The firm has a market capitalization of $159.72 million, a PE ratio of -2.85 and a beta of 0.48. The stock’s fifty day moving average is $2.03 and its 200-day moving average is $2.24.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. HC Wainwright raised Aclaris Therapeutics from a “neutral” rating to a “buy” rating and set a $20.00 price target for the company in a research note on Monday, December 23rd. Scotiabank assumed coverage on Aclaris Therapeutics in a research note on Friday, March 7th. They set a “sector outperform” rating and a $15.00 target price for the company. Cantor Fitzgerald started coverage on Aclaris Therapeutics in a report on Tuesday, March 18th. They set an “overweight” rating on the stock. Finally, StockNews.com downgraded shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, February 8th. One equities research analyst has rated the stock with a sell rating, seven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $11.67.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.